AstraZeneca Expects Exanta Experience To Benefit Future Anticoagulant R&D
Executive Summary
AstraZeneca's experience with its failed anticoagulant Exanta (ximelagatran) will provide the company an advantage going forward in developing new oral anticoagulants, VP and Cardiovascular Therapy Area Head Gunnar Olsson maintained